Medicare’s AI Coverage Pilot Triggers Warnings of Denials

Written by Bryan Potok on February 17, 2026
Last updated on February 17, 2026

Reading Time: 6 minutes

___

Summary:

CMS launches WISeR pilot using AI to screen Medicare prior authorizations
Program targets procedures deemed to be high-risk for fraud, waste, and abuse
Critics warn AI-driven reviews could increase coverage denials
Lawmakers push the Ban AI Denials in Medicare Act over transparency concerns
Pilot may reshape access to care for 6.5 million beneficiaries

___

On January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched a pilot program that uses artificial intelligence to screen “prior authorization” coverage claims. However, critics and patient advocacy groups warn that the initiative could lead to delayed care and unnecessary denials, raising troubling questions about transparency, fairness, and patient rights.

Medicare AI coverage pilot article image showing an older man with a below-knee prosthetic leg seated outdoors on a bench.

Here’s what we know about the program and the arguments for and against it so far.

The Context for the Pilot Program

Medicare, the U.S. federal health insurance program mainly serving those 65 and older, has historically struggled with fraud and waste—unneeded or improper medical services that increase costs without improving patient outcomes. Managed by CMS, Medicare funds hospital, medical, and prescription drug costs but faces ongoing difficulties in balancing cost containment with providing patients access to essential care.

Traditionally, prior authorization—requiring approval before certain medical procedures—has been conducted manually and criticized for delays and unjust denials. In response to an estimated $5.8 billion in wasteful spending reported in 2022, CMS launched the Wasteful and Inappropriate Service Reduction (WISeR) pilot program.

What is WISeR and How It Works

WISeR represents one of the most significant expansions of AI’s role in traditional Medicare yet. Under this six-year trial, which ends on December 21, 2031, CMS is collaborating with private contractors to use AI tools in reviewing coverage for a specific set of procedures that the agency deems high-risk for fraud, waste, and abuse.

According to CMS officials, WISeR targets services that “provide little to no clinical benefit,” such as skin and tissue substitutes, electrical nerve stimulators, and some diagnostic knee surgeries. Although AI won’t make the final decision on coverage, it will help flag potentially low-value requests and guide human reviewers—a blend of machine assessment and clinician oversight that CMS says will improve efficiency. Similar approaches already exist in private Medicare Advantage plans, where prior authorization and automated reviews are commonplace.

Although AI won’t make the final decision on coverage, it will help flag potentially low-value requests and guide human reviewers.

WISeR affects traditional Medicare beneficiaries in six states—Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington—and could influence care for nearly 6.5 million people who rely on original Medicare for their health coverage.

Concerns on Transparency and Denials

WISeR has triggered strong opposition from lawmakers and Medicare advocacy groups, who argue that CMS has not provided enough information about how the algorithms will operate, as well as how they will affect patients’ access to essential care. Critics warn that increasing AI-driven prior authorization might effectively become a method of denying coverage, echoing concerns raised about Medicare Advantage and private insurance practices.

In an interview with Bloomberg Law, David Lipschutz, co-director of law and policy at the Center for Medicare Advocacy, summarized the core concern: while prior authorization systems are intended to limit waste, they can also restrict care that physicians deem necessary, especially when early screening is left to opaque technologies.

Lawmakers have gone further, accusing the administration of withholding key information about algorithm design, contract terms with AI vendors, and financial incentives that might skew decisions toward denials. Some Democrat members of Congress have even introduced legislation—the Ban AI Denials in Medicare Act—to prevent CMS from advancing WISeR until these transparency issues are fully addressed.

Representative Greg Landsman (D-Ohio) warned that without transparency, doctors and healthcare providers might face impossible choices: either take financial hits when AI-flagged patient care is denied or stop providing essential services to avoid disputes. Essentially, providers could be penalized not for poor care, but for operating in a system where algorithmic alerts outweigh clinical judgment.

Without transparency, doctors and healthcare providers might face two choices: to take financial hits when AI-flagged patient care is denied or stop providing essential services to avoid disputes.

Efficiency vs. Access

Supporters of the pilot argue that AI could enhance Medicare’s sustainability, especially considering the program’s large scale and the longstanding challenge of eliminating improper payments. Automating parts of the prior authorization process and pairing it with human oversight may help minimize waste while protecting beneficiaries.

However, opponents see it as a slippery slope. Historically, traditional Medicare had minimal prior authorization requirements compared to private insurance, which helped ensure broad access to care. And adding AI risk flags could change how patients and providers interact with the program, potentially leading to delays, increased administrative workload, and more coverage denials.

Healthcare policy experts also argue that without transparency and strict external oversight, algorithm-driven decisions—particularly in critical areas like medical procedure access—might undermine trust in the healthcare system. When patients and providers cannot understand why a coverage request is denied or how AI reached its conclusion, it leads to not only uncertainty about care but also doubt about the fairness of Medicare itself.

Looking Ahead

As the WISeR pilot unfolds over the coming years, policymakers, advocates, and the general public will closely watch not only its immediate effects on access and costs but also whether this AI trial in traditional Medicare sets a precedent for wider use across the federal healthcare system.

If the critics are right, the pilot could lead to increased coverage denials and patient frustration. However, with proper safeguards and transparent oversight, some supporters believe the program could provide valuable insights on modernizing Medicare while maintaining equitable access. Regardless of the results, this is a critical turning point in the government’s use of AI in important health decisions.

Insurance Denied Her Prosthetic, She Fought to Walk at Graduation

Medicare and Prosthetic Limbs: Coverage for Amputees Explained